Active, Not Recruiting
A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02734771
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, United States
- University of Virginia Cancer Center Charlottesville, Virginia, United States